Examination of Org 26576, an AMPA receptor positive allosteric modulator, in patients diagnosed with major depressive disorder: An exploratory, randomized, double-blind, placebo-controlled trial

Journal of Psychopharmacology

Volumn 26, Issue 12, 2012, Pages 1525-1539

  Nations, Kari R ^a   Dogterom, Peter ^b   Bursi, Roberta ^b   Schipper, Jacques ^b   Greenwald, Scott ^c   Zraket, David ^c   Gertsik, Lev ^d   Johnstone, Jack ^e   Lee, Allen ^a   Pande, Yogesh ^a   Ruigt, Ge ^b   Ereshefsky, Larry ^d,f  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NV ORGANON   (Netherlands)

^c MEDTRONIC INC   (United States)

^d CALIFORNIA CLINICAL TRIALS   (United States)

^e Q Metrx   (United States)

^f UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

AMPA receptor positive allosteric modulator; emotional processing; major depressive disorder; Org 26576; QEEG

Indexed keywords

8,9,9A,10 TETRAHYDRO 5H 7H PYRIDO[3,2 F]PYRROLO[2,1 C][1,4]OXAZEPINE 5 ONE; AMPA RECEPTOR POSITIVE ALLOSTERIC MODULATOR; ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; ORG 26576; PLACEBO; UNCLASSIFIED DRUG;

ABNORMAL DREAMING; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ATTENTION DISTURBANCE; BACKACHE; COGNITION; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EXECUTIVE FUNCTION; FATIGUE; FEELING DRUNK; FEMALE; HEART PALPITATION; HUMAN; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MUSCLE TWITCH; NAUSEA; NEUROLOGIC EXAMINATION; NOSE OBSTRUCTION; PARALLEL DESIGN; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; POST LUMBAR PUNCTURE SYNDROME; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL; SEDATION; SENSORY DYSFUNCTION; SIDE EFFECT; SOCIAL ACUITY; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; ALLOSTERIC REGULATION; ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMAN GROWTH HORMONE; HUMANS; HYDROCORTISONE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, AMPA; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84870427621     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881112458728     Document Type: Article

References (67)

1. Adler LA, Kroon RA, Stein M, et al. A translational approach to evaluate the efficacy and safety of the novel AMPA receptor positive allosteric modulator org 26576 in adult attention-deficit/hyperactivity disorder. Biological Psychiatry. 2012 ;:
2. Aguilar E, Tena-Sempere M, Pinilla L. Role of excitatory amino acids in the control of growth hormone secretion. Endocrine. 2005 ; 28: 295-302
3. Ahmed AH, Calvird M, Gordon RD, et al. Effects of two selective serotonin reuptake inhibitor antidepressants, sertraline and escitalopram, on aldosterone/renin ratio in normotensive depressed male patients. J Clin Endocrinol Metab. 2011 ; 96: 1039-1045
4. Alt A, Nisenbaum ES, Bleakman D, et al. A role for AMPA receptors in mood disorders. Biochem Pharmacol. 2006 ; 71: 1273-1288
5. Practice Guideline for the Treatment of Patients with Major Depressive Disorder. 2010 ) Practice Guideline for the Treatment of Patients with Major Depressive Disorder. (3rd ed) Arlington, Virginia: American Psychiatric Association. Arlington, Virginia: American Psychiatric Association ; 2010 :
6. Arai AC, Kessler M. Pharmacology of ampakine modulators: from AMPA receptors to synapses and behaviour. Curr Drug Targets. 2007 ; 8: 583-602
7. Asada H, Fukuda Y, Tsunoda S, et al. Frontal midline theta rhythms reflect alternative activation of prefrontal cortex and anterior cingulate cortex in humans. Neurosci Lett. 1999 ; 274: 29-32
8. Austin MP, Mitchell P, Goodwin GM. Possible implications for functional neuropathology. Br J Psychiatry. 2001 ; 178: 200-206
9. Bai F, Bergeron M, Nelson DL. Chronic AMPA receptor potentiator (LY451646) treatment increases cell proliferation in adult rat hippocampus. Neuropharmacology. 2003 ; 44: 1013-1021
10. Bares M, Brunovsky M, Kopecek M, et al. Early reduction in prefrontal theta QEEG cordance value predicts response to venlafaxine treatment in patients with resistant depressive disorder. Eur Psychiatry. 2008 ; 23: 350-355
11. Bares M, Brunovsky M, Novak T, et al. The change of prefrontal QEEG theta cordance as a predictor of response to bupropion treatment in patients who had failed to respond to previous antidepressant treatments. Eur Neuropsychopharmacol. 2010 ; 20: 459-466
12. Bearden CE, Freimer NB. Endophenotypes for psychiatric disorders: ready for primetime?. Trends Genet. 2006 ; 22: 306-313
13. Beck AT, Steer RA, Ranieri WF. Scale for suicide ideation: psychometric properties of a self-report version. J Clin Psychol. 1988 ; 44: 499-505
14. Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endoc Rev. 2001 ; 22: 724-763
15. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000 ; 47: 351-354
16. Bursi R, Erdemli G, Campbell R, et al. Translational PK-PD modelling of molecular target modulation for the AMPA receptor positive allosteric modulator Org 26576. Psychopharmacology. 2011 ; 218: 713-724
17. Cohen J Statistical Power Analysis for the Behavioral Sciences. 1988 ) Statistical Power Analysis for the Behavioral Sciences. (2nd ed) Hillsdale, New Jersey: Lawrence Erlbaum Associates. Hillsdale, New Jersey: Lawrence Erlbaum Associates ; 1988 :
18. Cook IA, Leuchter AF. Prefrontal changes and treatment response prediction in depression. Semin Clin Neuropsychiatry. 2001 ; 6: 113-120
19. Cook IA, Leuchter AF, Morgan M, et al. Early changes in prefrontal activity characterize clinical responders to antidepressants. Neuropsychopharmacology. 2002 ; 27: 120-131
20. Crown WH, Finkelstein S, Berndt ER, et al. The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry. 2002 ; 63: 963-971
21. Du J, Gray NA, Falke CA, et al. Modulation of synaptic plasticity by antimanic agents: the role of AMPA glutamate receptor subunit 1 synaptic expression. J Neurosci. 2004 ; 24: 6578-6589
22. Erdemli G, Smith LH, Sammons M, et al. Org 26576, a novel positive allosteric modulator, potentiates AMPA receptor responses in hippocampal neurones. European Neuropsychopharmacology. 2007 ; 17: S46
23. Frye MA, Tsai GE, Huggins T, et al. Low cerebrospinal fluid glutamate and glycine in refractory affective disorder. Biol Psychiatry. 2006 ; 61: 162-166
24. Goff DC, Lambert JS, Leon AC, et al. A placebo-controlled add-on trial of the ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacol. 2008 ; 33: 465-472
25. Goff D, Leahy L, Berman I, et al. A placebo-controlled pilot study of the ampakine, CX516, added to clozapine in schizophrenia. J Clin Psychopharmacol. 2001 ; 21: 484-487
26. Gonzalez LC, Pinilla L, Tena-Sempere M, et al. Regulation of growth hormone secretion by alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors in infantile, prepubertal, and adult male rats. Endocrinology. 1999a ; 140: 1279-1284
27. Gonzalez LC, Pinilla L, Tena-Sempere M, et al. Role of alpha-amino-3-hydroxy-5-methylisoxazole-. 4-propionic acid receptors in the control of prolactin, growth hormone and gonadotropin secretion in prepubertal rats. J Endocrinol. 1999b ; 162: 417-424
28. Gualtieri CT, Johnson LG. Reliability and validity of a computerized cognitive test battery, CNS vital signs. Arch of Clin Neuropsychology. 2006 ; 21: 623-643
29. Guy W ECDEU Assessment Manual for Psychopharmacology. Guy W, ed. Washington, DC: U.S. Department of Health, Education, and Welfare ; 1976: 217-222.
30. Hamlyn E, Brand L, Shahid M, et al. The ampakine, Org 26576, bolsters early spatial reference learning and retrieval in the Morris water maze: a subchronic, dose-ranging study in rats. Behav Pharmacol. 2009 ; 20: 662-667
31. Hashimoto K, Sawa A, Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry. 2007 ; 62: 1310-1316
32. Hergovich N, Singer E, Agneter E, et al. Comparison of the effects of ketamine and memantine on prolactin and cortisol release in men: a randomized, double blind, placebo-controlled trial. Neuropsychopharmacology. 2001 ; 24: 590-593
33. Karege F, Perret G, Bondolfi G, et al. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res. 2002 ; 109: 143-148
34. Knapp RJ, Goldenberg R, Shuck C, et al. Antidepressant activity of memory-enhancing drugs in the reduction of submissive behavior model. Eur J Pharmacol. 2002 ; 440: 27-35
35. Koscis J. New strategies for treating chronic depression. J Clin Psychiatry. 2000 ; 60: S42 - S45
36. Lauterborn JC, Lynch G, Vanderklish P, et al. Positive modulation of AMPA receptors increases neurotrophin expression by hippocampal and cortical neurons. J Neurosci. 2000 ; 20: 8-21
37. Lauterborn JC, Truong GS, Baudry M, et al. Chronic elevation of brain-derived neurotrophic factor by ampakines. J Pharmacol Exp Ther. 2003 ; 307: 297-305
38. Legutko B, Li X, Skolnick P. Regulation of BDNF expression in primary neuron culture by LY392098, a novel AMPA receptor potentiator. Neuropharmacology. 2001 ; 40: 1019-1027
39. Leuchter AF, Cook IA, Gilmer WS, et al. Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder. Psychiatry Res. 2009a ; 169: 132-138
40. Leuchter AF, Cook IA, Marangell LB, et al. Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in major depressive disorder: results of the BRITE-MD study. Psychiatry Res. 2009b ; 169: 124-131
41. Leuchter AF, Cook IA, Witte EA, et al. Changes in brain function of depressed subjects during treatment with placebo. Am J Psychiatry. 2002 ; 159: 122-129
42. Leuchter AF, Uijtdehaage SH, Cook IA, et al. Relationship between brain electrical activity and cortical perfusion in normal subjects. Psychiatry Res. 1999 ; 90: 125-140
43. Li X, Tizzano JP, Griffey K, et al. Antidepressant-like actions of an AMPA receptor potentiator (LY392098). Neuropharmacology. 2001 ; 40: 1028-1033
44. Lynch G. Glutamate-based therapeutic approaches: ampakines. Curr Opin Pharmacol. 2006 ; 6: 82-88
45. Maeng S, Zarate CA, Du J, et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of α-amino-3-hydroxy-5- methylisoxazole-4-propionic acid receptors. Biol Psychiatry. 2008 ; 63: 349-352
46. Marenco S, Egan MF, Goldberg TE, et al. Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: a case series. Schizophr Res. 2002 ; 57: 221-226
47. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002-2030. PLoS Med. 2006 ; 3: 2011-2030
48. Matrisciano F, Bonaccorso S, Ricciardi A, et al. Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine. J Psychiatr Res. 2009 ; 43: 247-254
49. Mitani H, Shirayama Y, Yamada T, et al. Correlation between plasma levels of glutamate, alanine and serine with severity of depression. Prog Neuropsychopharmacol Biol Psychiatry. 2006 ; 30: 1155-1158
50. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979 ; 134: 382-389
51. Nations KR, Bursi R, Dogterom P, et al. Maximum tolerated dose evaluation of the AMPA receptor positive allosteric modulator Org 26576 in healthy volunteers and depressed patients: a summary of bridging research in support of Phase 2 dose selection. Drugs R D. 2012 ;:
52. Noorbala AA, Akhondzadeh S, Davari-Ashtiani R, et al. Piracetam in the treatment of schizophrenia: implications for the glutamate hypothesis of schizophrenia. J Clin Pharm Ther. 1999 ; 24: 369-374
53. Pizzagalli DA. Frontocingulate dysfunction in depression: toward biomarkers of treatment response. Neuropsychopharmacology. 2010 ; 36: 1-24
54. Pizzagalli DA, Oakes TR, Davidson RJ. Coupling of theta activity and glucose metabolism in the human rostral anterior cingulate cortex: an EEG/PET study of normal and depressed subjects. Psychophysiology. 2003 ; 40: 939-949
55. Pringle A, Browning M, Cowen PJ, et al. A cognitive neuropsychological model of antidepressant drug action. Prog Neuropsychopharmacology Biol Psychiatry. 2011 ; 35: 1586-1592
56. O'Neill MJ, Witkin JM. AMPA receptor potentiators: application for depression and Parkinson's disease. Curr Drug Targets. 2007 ; 8: 603-620
57. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-item Quick Inventory of Depressive Symptomatology (QIDS) Clinician Rating (QIDS-C) and Self-Report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003 ; 54: 573-583
58. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006 ; 163: 1905-1917
59. Sen S, Duman R, Sanacora G. Serum BDNF, depression, and anti-depressant medications: meta-analyses and implications. Biol Psychiatry. 2008 ; 64: 527-532
60. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The MINI International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1997 ; 59: 22-33
61. Su XW, Li XY, Banasr M, et al. Chronic treatment with AMPA receptor potentiator Org 26576 increases neuronal cell proliferation and survival in adult rodent hippocampus. Psychopharmacology. 2009 ; 206: 215-222
62. Swann JW, Smith KL, Brady RJ. Localized excitatory synaptic interactions mediate the sustained depolarization of electrographic seizures in developing hippocampus. J Neurosci. 1993 ; 13: 4680-4689
63. Tranter R, Bell D, Gutting P, et al. The effect of serotonergic and noradrenergic antidepressants on face emotion processing in depressed patients. J Affect Disord. 2009 ; 118: 87-93
64. Warner-Schmidt JL, Duman RS. VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants. Proc Natl Acad Sci USA. 2007 ; 104: 4647-4652
65. Wittchen HU, Jacobi F, Rehm J, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011 ; 21: 655-679
66. Zarate CA, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment resistant major depression. Arch Gen Psychiatry. 2006 ; 63: 856-864
67. Zimmerman M, Posternak MA, Chelminski I. Derivation of a definition of remission on the Montgomery-Asberg depression rating scale corresponding to the definition of remission on the Hamilton rating scale for depression. J Psychiatr Res. 2004 ; 38: 577-582